MTX228 in Type 1 Diabetes
Type 1 DiabetesMTX228 has been identified as a medication that might promote the regeneration of the cells that produce insulin. This would be beneficial to people with Type 1 Diabetes because it would allow them to take less insulin by injection and would improve their overall blood sugar control while reducing their risk of low blood sugars. This open-label dose selection study will test several different doses of tolimidone to see which one works best. The best dose will then be further tested in another study.
null
Participation Requirements
-
Sex:
Any -
Eligible Ages:
18 to 65
Participation Criteria
Inclusion Criteria:
1) Type 1 Diabetes:
-if diagnosed before 35 years of age, continuous insulin therapy must have been started within 1 year of diagnosis
-if diagnosed after 35 years of age, the presence of positive Type 1 Diabetes antibodies must be documented
-diagnosed for at least 1 year at the time of screening
2) HbA1c between 6-10%
3) BMI ≤ 35 kg/m2
4) Willing to wear study provided CGM and able to share CGM data via cloud.
Exclusion Criteria:
1) Monogenic diabetes, Type 2 Diabetes, or post-pancreatectomy diabetes.
2) History of severe hypoglycemia.
3) Use of medications other than insulin to control blood sugars.
4) Any other major or unstable medical conditions, including a history of cancer within the last 5 years before screening.
5) Pregnant, breastfeeding, or planning to become pregnant during the course of the study.
Study Location
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Alberta
- Participants Required
- More Information
- Study ID:
NCT06474598